Reimbursement News Reimbursement news and insurance coverage updates. Sep 2, 2022 In Brief This Week: PreludeDx, Ochsner Health, Avacta Group, Guardant Health, Caris Life Sciences Aug 31, 2022 Oncocyte Nets $3M VA Contract for DetermaRx Lung Cancer Prognostic Test Aug 26, 2022 Myriad Genetics Gets Expanded Coverage for BRACAnalysis CDx in Japan Aug 2, 2022 Guardant Health Receives Medicare Coverage for MRD Liquid Biopsy in Stage II and III Colon Cancer Jul 28, 2022 Merck's Keytruda Q2 Sales Grow 26 Percent; Firm Considers Future Impact of Medicare Price Setting Premium Jul 28, 2022 Adaptive Biotech's ClonoSeq Gets Expanded Medicare Coverage For B-Cell Lymphoma Jul 7, 2022 Doctors, Payors, Lab Directors, Patients Have Distinct Views on What's Holding Up Precision Oncology Jun 30, 2022 CMS Retains Unspecified Cancer Dx Codes After Industry Stakeholder Feedback Premium May 20, 2022 Palmetto Finalizes Positive LCD for Prostate Cancer Risk Tests May 12, 2022 ESMO Advances Biomarker Framework to Guide Cancer Therapy De-Intensification, Decision-Making Premium Apr 4, 2022 MNM Bioscience Wins $800K Eurostars Grant to Stratify Ovarian Cancer Patients Feb 24, 2022 Medicare Contractor's Final Coverage Decision on NGS Cancer Testing Appeases Industry Stakeholders Premium Feb 22, 2022 Expert Reviews of NGS Reports Helping Community Docs Clear 'Last Mile' Hurdle in Precision Oncology Premium Feb 11, 2022 Healthcare Stakeholders Redefine Cancer Multigene Testing Clinical Utility Hoping to Spur Adoption Premium Feb 4, 2022 In Brief This Week: Aspira Women's Health, Sprinter Health, Naveris, Sophia Genetics, Theseus, Syros Jan 31, 2022 CMS No Longer Reimbursing Interpace Bio Thyroid Tests; Firm's Rights Offering Terminated Jan 18, 2022 Takeda, Point32Health Deal Could Offer Roadmap for Risk-Sharing Reimbursement in Precision Oncology Premium Dec 30, 2021 Top 10 Precision Oncology Articles in 2021: Liquid Biopsy, Difficult Reimbursement, TMB Debates Nov 30, 2021 NICE Backs AstraZeneca's Tagrisso for Adjuvant EGFR-Mutated NSCLC Through Cancer Drugs Fund Nov 29, 2021 Genetic Testing Challenges in Oncology: No Follow-up on Insurer Denial Delays Cancer Risk Management Load More Breaking News Ratio Therapeutics Raises $20M in Series A Financing Guardant Health, AnHeart Tx to Develop Blood- and Tissue-Based CDx for NSCLC Drug Ellipses Pharma Cleared by FDA to Open Phase I/II AML Trial Survey Reveals Changing Genetic Testing Patterns, Persistent Disparities in Precision Oncology Amgen's Lumakras Sales Increased 58 Percent in Q4 2022 Coeptis Therapeutics, University of Pittsburgh Studying SNAP-CAR Therapy in HER2-Positive Cancers
